Clinical Trial - Taking Part

TauRx’s tau aggregation inhibitors are the product of nearly 30 years of research, preclinical and clinical investigations.

Our second-generation tau aggregation inhibitor has completed four separate Phase 3 trials: three in Alzheimer's disease and one in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD).

Our latest phase 3 clinical trial, named LUCIDITY, included participants with mild cognitive impairment, mild Alzheimer’s, and mild-moderate Alzheimer’s.

Nearly 600 patients were recruited to the trial, which completed in mid-2023. The trial used well-accepted cognitive and functional assessment scales to assess the effectiveness of the drug in delaying the progression of Alzheimer’s disease and included an open-label phase during which all participants received the drug at the predicted optimal dose of 16mg per day. Full results of the study will be available soon.

Additional information on the study is also available here.